MedTrace Logo

Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial

NCT00407797 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2021-01-25

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the clinical improvement by partial seizures reduction, safety and tolerability of subjects having partial epilepsy related to the adjunction of pregabalin BID (75 to 300mg day titration, BID) to existing standard AED (Antiepileptic drugs).

Conditions

  • Partial Seizures

Interventions

DRUG

Pregabalin

150 to 600 mg/day during 21 weeks

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00407797 on ClinicalTrials.gov